Articles by James C. Greenwood - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by James C. Greenwood

Prescribing Caution for Biosimilars

Apr 2, 2013

Sound policies are needed to govern the substitution of interchangeable biologics.

Intellectual Property as the Foundation of Innovation

Supportive public policy is needed in order for innovation to flourish.
Dec 2, 2010

Supportive public policy is needed in order for innovation to flourish.

Delivering on the Promise of Biotechnology

The BIO convention, and healthcare reform, could re-energize biotech.
Apr 2, 2010

The BIO convention, and healthcare reform, could re-energize biotech.

Healthcare Reform Requires Room for Innovation

To move from R&D to breakthrough drugs, biotech companies need policies that support innovation.
Jan 2, 2010

To move from R&D to breakthrough drugs, biotech companies need policies that support innovation.

Progress Made on the Path to Biosimilars

BIO supports recent Congressional action toward a 12-year data exclusivity period for innovators.
Oct 2, 2009

BIO supports recent Congressional action toward a 12-year data exclusivity period for innovators.

Biotechnology in 2009

The president of BIO proposes the ingredients needed for industry growth.
May 2, 2009

The president of BIO proposes the ingredients needed for industry growth.

Industry Leaders Debate Follow-on Biologics Pathway

The organizations' presidents discuss market exclusivity, approval processes, and pending legislation.
May 2, 2009

The organizations' presidents discuss market exclusivity, approval processes, and pending legislation.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here